16 November 2021
Visiongain has launched a new report Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2021-2031: Forecasts by Molecule Type (Small Molecule, Large Molecule), by Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Others), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Others), by Service (Bioanalytical Testing, Method Development & Validation, Stability Testing, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios.
Global Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Outlook
According to Visiongain analysis, Global Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market was valued at US$xx million in 2020. The global market is expected to witness a CAGR of xx% from 2021 to 2026 and is expected to reach US$xx million in 2026 from its previous value of US$xx million in 2021. Visiongain further anticipates that the region will reach US$xx million in 2031 while growing at a CAGR of xx% from 2021 to 2031.
What are the Market Drivers?
Manufacturing Costs Across Asia Pacific Area Are Much Cheaper Compared to North America and Europe
Manufacturing costs in the Asia Pacific area are much cheaper than in North America and Europe, and favourable regulations are helping to drive the CMO of sterile injectable drugs industry's expansion. Despite the fact that API manufacturing services have mostly moved to China and India, the United States is still the dominant location for pharmaceutical development outsourcing. This is mostly because to the vast quantities of financing available and the particular concentration of pharmaceutical research clusters connected with universities. Developing nations are also unfavourable for outsourcing pharmaceutical development because of concerns with quality, logistics, laws, and intellectual property rights.
Sterile Injectables are Overtaking Solid Dosage Forms Which is Projected to Boost CMO of Sterile Injectable Drugs Market Growth
Sterile injectables are overtaking solid dosage forms as the fastest-growing category in the pharmaceutical development and manufacture outsourcing business, which has long been dominated by solids. The growing relevance of biologics is a major factor in the sterile injectable market's rapid expansion. The outsourcing of research and production operations for solids, semisolids, and non-sterile liquids will continue to grow, albeit at a slower rate than sterile liquids.
What are the Market Opportunities?
Demand for Prefilled Syringes is Projected to Grow Through 2031
Demand for prefilled syringes is increasing as chronic illness incidence rises, technology advances, self-injecting parenteral device use rises, and supporting government laws encourage growth in the prefilled syringe industry (especially needlestick legislations). Prefilled syringes are rising in popularity among patients and healthcare professionals, as well as the pharmaceutical industry as a whole, due to the expanding number of biologics and biosimilars.
Drug production and supply chain are projected to be affected by the pandemic, which will have a short-term effect on the prefilled syringes industry. Virtual healthcare and digital technology must be adopted by healthcare providers (HCPs) in order to enable them to continue their regular visits, and HCPs have adapted to new methods of providing treatment via telemedicine. Apps may also help with self-management of chronic illnesses, such as diabetes, which can benefit from continuous glucose monitoring. COVID-19 epidemic will need a lot from community pharmacists, who may help alleviate the impact on already stretched health systems by managing chronic diseases and encouraging drug adherence.
Prefilled syringes are more expensive to acquire than disposable syringes because of the high production costs. The traditional intrusive and unpleasant nature of injectables is one of the primary reasons people choose oral, topical, and nasal medication delivery methods. Drugs may be taken orally since it is the most convenient, cost-effective and safe method of administration. These issues have led to a worldwide increase in the use of alternate medication delivery systems. Injectable insulin is being phased out in favour of less expensive delivery systems like Pfizer's Exubera (inhalable insulin) and Medtronic's Veo insulin pump (inhalable insulin). Insulin injections are a substantial market for injectable drug delivery systems since they are the most common method of administering insulin. It is projected that the introduction of inhalable insulin, which is painless and highly patient-compliant, would greatly affect the development of this market. Another factor that might hurt the expansion of injectable technologies is the development of other delivery methods for additional disease indications, such as oral anaemia therapy by GlaxoSmithKline and Bayer, in the future.
Diversifying Service Offerings to Boost Market Growth Over the Next Decade
By diversifying their service offerings, contract manufacturing organisations (CMOs) may enhance their core competencies and position themselves as one-stop shops for a particular dosage form. Horizontal integration, on the other hand, is more expensive and riskier since the CMO has to start from scratch. Cross-selling new services to current clients is made possible by this solution, which also meets the majority of legal requirements. Both vertically and horizontally, CMOs wishing to expand their business have two options: they can either provide additional services for current dosage forms or API manufacturing, or they may offer the same services for new dosage forms. Horizontal integration decreases a CMO's reliance on a single dosage form, whereas vertical integration is easier in certain circumstances.
Many CMOs fear that the market will become more consolidated. It's possible that smaller CMOs won't be able to compete with the rising number of major CMOs, who are constantly expanding their services and technical capabilities by purchasing other market players. It's also possible that they won't be able to compete for the best staff. CMOs must compete for talent not just with their nearby rivals but also with major, global pharmaceutical corporations for qualified scientists and experienced project managers. Poor-volume formulations, such as specialty and orphan medications, are increasingly being outsourced by pharmaceutical corporations because of their high risk and low income. Some CMOs must depend on only one or a few clients for the majority of their income because of the market's present high degree of fragmentation. This kind of reliance puts the client in a position of considerable bargaining power, which gives them the ability to exert downward pressure on pricing. Cost reduction initiatives by the government and tighter regulation in many nations are putting further pressure on prices.
COVID-19 Impact Analysis on Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market
There has been a surge in demand for sterile vials since pharmaceutical firms joined the COVID-19 vaccine manufacturing competition. They are taking advantage of this opportunity and working at breakneck speed to ensure that their supply networks remain healthy. The Stevanato Group, a biopharmaceutical packaging and delivery company, has increased manufacturing of sterile vials for COVID-19 vaccines. When coronavirus lockdowns and curfews are in place, more patients and persons are stocking up on medical supplies, which helps producers in the sterile vials market remain in business during the peak pandemic time.
Meanwhile, pharmaceutical corporations are examining main packaging options to fill, store, and deliver billions of vaccine doses over the globe. Due to an unanticipated and unprecedented demand for sterile vials, borosilicate glass is in limited supply across the world. Drug effectiveness and stability may be compromised by the use of conventional polymers. There is an increased focus on developing hybrid packaging solutions incorporating SiO2 (Silica) materials, which combines the advantages of both glass and plastic without any of their downsides.
High quality sterile and depyrogenated moulded glass vials are becoming more widely available in the pharmaceutical primary packaging business as a result of increased production in the sterile vial market. For lyophilization, ISO-compliant standard finish necks and sturdy packing in vials are used because of their ability to endure severe temperatures. Sterile vial manufacturers are reaping the benefits of new packaging options for oral liquids for human health and sterile injectables for animal healthcare. One of the world's largest publicly listed multinational conglomerates in the United States, Honeywell International Inc., has introduced their Aclar Edge pharmaceutical packaging solution, which uses its unique multi-layer extrusion blow moulding technology. In order to increase user safety during handling and administration, manufacturers are following the lead of such advancements.
Sterilized vial sales are expected to continue to rise as a result of the ever-changing nature of COVID-19 strains and the reported infection of persons between their first and second doses of vaccination. Sterile injectables for vials segment is projected to reach a value of $15,983.5 by 2031. Lyophilization glass vials have been plagued with breakage, fractures, and delamination for years, which has resulted in several product recalls. In order to keep vials safe and avoid contamination, organisations should partner with the best machine suppliers to develop new and stronger materials.
The best CMOs don't simply focus on one market segment; they specialise in a variety of markets in order to protect themselves from the hazards of each one. There is ample time for a CMO to find alternative methods to fill its manufacturing lines if a product at danger is just a small percentage of sales. However, it's not an easy process to specialise in numerous fields. An uncorrelated specialisation means there are no synergies between the many specialties, more investment in skills, and a better understanding of the market's best commercial prospects to diversify the risk.
Therefore, navigating this market is difficult. Outsourcing continues to develop at a rapid pace as a result of strong pharmaceutical markets, increasing activity from generics and a rise in outsourcing. Everything indicates that market participants will specialise and possibly multi-specialize in the next years. If private equity players and other investors have a strong grasp of where a CMO's competitive advantage rests, this market expansion may give excellent returns. It's possible to reap significant benefits by developing expertise based on an in-depth understanding of the industry.
Some of the major companies operating in the global Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market are Aenova Group, Almac Group, Baxter Biopharma Solutions, Boehringer Ingelheim, Catalent, Inc., CordenPharma, Evonik Industries AG, Famar Health Care Services, Fresenius Kabi Ag, Grifols SA, Hikma Pharmaceuticals PLC, Jubilant Pharmova Limited, Lonza, Patheon, Inc. (Thermo Fischer), Pfizer CentreOne, Recipharm AB, and Siegfried Holding AG among other prominent players. To gain a competitive edge, Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs companies adopt a variety of strategies. These include product launch, investment in R&D, partnerships, regional business expansion, mergers & acquisitions, and facility expansion.
Discover sales predictions for the global Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market and submarkets.
Along with revenue prediction for the overall world market, there are 6 segmentations of the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market, with forecasts for 2 molecule types, 8 types, 6 applications, 5 container types, 4 route of administration, and 4 services, each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.
Who are the leading players analysed in the market?
• Aenova Group
• Almac Group
• Baxter Biopharma Solutions
• Boehringer Ingelheim
• Catalent, Inc.
• Evonik Industries AG
• Famar Health Care Services
• Fresenius Kabi Ag
• Grifols SA
• Hikma Pharmaceuticals PLC
• Jubilant Pharmova Limited
• Lonza, Patheon, Inc. (Thermo Fischer)
• Pfizer CentreOne
• Recipharm AB
• Siegfried Holding AG
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Pharma Wholesale and Distribution market is estimated at US$844.2 billion in 2024 and is projected to grow at a CAGR of 8.7% during the forecast period 2024-2034.
20 February 2024
The global Biobanking market is estimated at US$75.4 billion in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period 2024-2034.
19 February 2024
The Dermatological Drugs market is estimated at US$30.47 billion in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period 2024-2034.
13 February 2024
The global Allergic Rhinitis Drugs market is estimated at US$16,821.6 million in 2024 and is expected to register a CAGR of 2.7% from 2024 to 2034.